Capecitabine in carcinoma of the pancreas

Bibliography

• JEMAL A, MURRAY T, WARD E et al.: Cancer statistics 2005. CA Cancer J. Clin. (2005) 55:10-30.
   PubMed Web of Science ®Google Scholar
• BRAMHALL SR, ALLUMWH, JONES AG, ALLWOOD A, CUMMINS C, NEOPTOLEMOS JP: Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br. J. Surg. (1995) 82(1):111-115.
   PubMed Web of Science ®Google Scholar
• PLATH T, PETERS M, DETJEN K et al.: Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis. J. Natl. Cancer Inst. (2002) 94:129-142.
   PubMedGoogle Scholar
• CARTER SK, COMIS RL: The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat. Rev. (1975) 2:193-214.
   PubMed Web of Science ®Google Scholar
• CROWN J, CASPER ES, BOTET J et al.: Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J. Clin. Oncol. (1991) 9:1682-1686.
   PubMed Web of Science ®Google Scholar
• DECAPRIO JA, MAYER RJ, GONIN R, ARBUCK SG: Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a Phase II trial. J. Clin. Oncol. (1991) 9:2128-2133.
   PubMed Web of Science ®Google Scholar
• VAN RIJSWIJK RE, JEZIORSKI K, WAGENER DJ et al.: Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a Phase II study of the EORTC Gastro-Intestinal Tract Cancer Cooperative Group. Eur. J. Cancer (2004) 40:2077-2081.
   PubMed Web of Science ®Google Scholar
• CASPER ES, GREEN MR, KELSEN DP et al.: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs (1994) 12:29-34.
   PubMed Web of Science ®Google Scholar
• CARMICHAEL J, FINK U, RUSSELL RC et al.: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer (1996) 73:101-105.
   PubMed Web of Science ®Google Scholar
• ROTHENBERG ML, MOORE MJ, CRIPPS MC et al.: A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas. Ann. Oncol. (1996) 7:347-353.
   PubMed Web of Science ®Google Scholar
• BURRIS HA III, MOORE MJ, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. (1997) 15:2403-2413.
   PubMed Web of Science ®Google Scholar
• THIRION. P, MICHIELS S, PIGNON JP et al.: Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol. (2004) 22(18):3766-3775.
   PubMed Web of Science ®Google Scholar
• MIWA M, URA M, NISHIDA M et al.: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer (1998) 34:1274-1281.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA T, UTOH M, SAWADA N et al.: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem. Pharmacol. (1998) 55(7):1091-1097.
   PubMed Web of Science ®Google Scholar
• SCHULLER J, CASSIDY J, DUMONT E et al.: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. (2000) 45:291-297.
   PubMed Web of Science ®Google Scholar
• REIGNER B, BLESCH K, WEIDEKAAM E: Capecitabine; a review of its clinical pharmacokinetics. Clin. Pharmacokinet. (2001) 40:85-104.
   PubMed Web of Science ®Google Scholar
• NAKAYAMA Y, INOUE Y, NAGASHIMA N et al.: Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer. Anti-Cancer Res. (2005) 25(6A):3755-3761.
   PubMed Web of Science ®Google Scholar
• PASSANTINO L, AMATI L, CIANCIOTTA A et al.: Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages. Immunopharmacol. Immunotoxicol. (2005) 27(1):95-107.
   PubMed Web of Science ®Google Scholar
• JUDSON I, BEALE P, TRIGO J et al.: A human capecitabine excretion balance and pharmacokinetic study after administration of asingle oral dose of 14C-labelled drug. Invest. New Drugs (1999) 17:49-56.
   PubMed Web of Science ®Google Scholar
• TWELVES C, GLYNNE-JONES R, CASSIDY J et al.: Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin. Cancer Res. (1999) 5:1696-1702.
   PubMed Web of Science ®Google Scholar
• POOLE C, GARDINER J, TWELVES C et al.: Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother. Pharmacol. (2002) 49:225-234.
   PubMed Web of Science ®Google Scholar
• CAMIDGE R, REIGNER B, CASSIDY J et al.: Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J. Clin. Oncol. (2005) 23(21):4719-4125.
   PubMed Web of Science ®Google Scholar
• BRICKELL K, PORTER D, THOMPSON P: Phenytoin toxicity due to fluoropyrimidines (5-FU/capecitabine): three case reports. Br. J. Cancer (2003) 89:615-616.
   PubMed Web of Science ®Google Scholar
• REIGNER B, CLIVE S, CASSIDY J et al.: Influence of the antacid maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother. Pharmacol. (1999) 43:309-315.
   PubMed Web of Science ®Google Scholar
• BUDMAN DR, MEROPOL NJ, REIGNER B: Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J. Clin. Oncol. (1998) 16:1795-1802.
   PubMed Web of Science ®Google Scholar
• SCHEITHAUER W, MCKENDRICK J, BEGBIE S et al.: X-ACT Study Group. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, Phase III trial. Ann. Oncol. (2003) 14(12):1735-1743.
   PubMed Web of Science ®Google Scholar
• VAN CUTSEM E, HOFF PM, BLUM JL et al.: Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with fluorouracil. Ann. Oncol. (2002) 13(3):484-485.
   PubMed Web of Science ®Google Scholar
• SCHULL B, SCHEITHAUER W, KORNEK GV: Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. Onkologie (2003) 26(6):578-580.
   PubMedGoogle Scholar
• CARTWRIGHT TH, COHN A, VARKEY JA et al.: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J. Clin. Oncol. (2002) 20(1):160-164.
   PubMed Web of Science ®Google Scholar
• SAWADA N, FUJIMOTO-OUCHI K, ISHIKAWA T et al.: Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc. Am. Assoc. Cancer Res. (2002). (Abstract 5388.)
   Google Scholar
• HESS V, SALZBERG M, BORNER M et al.: Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a Phase I/II trial. J. Clin. Oncol. (2003) 21(1):66-68.
   PubMed Web of Science ®Google Scholar
• HEINEMANN V, HOEHLER T, SEIPELT G et al.: Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (GemCap) versus gemcitabine plus oxaliplatin (GemOx): a randomised Phase II trial in advanced pancreatic cancer. Proc. Am. Assoc. Clin. Oncol. (2005) 23. (Abstract 4030).
   Google Scholar
• SCHEITHAUER W, SCHULL B, ULRICH-PUR H et al.: Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized Phase II trial. Ann. Oncol. (2003) 14(1):97-104.
   PubMed Web of Science ®Google Scholar
• HERRMANN R, BODOKY G, RUHSTALLER T et al.: Gemcitabine (G) plus capecitabine versus G alone in locally advanced or metastatic pancreatic cancer. A randomized Phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). Proc. Am. Assoc. Clin. Oncol. (2005). (Abstract 4010.)
   Google Scholar
• CUNNINGHAM D, CHAU I, STOCKEN D et al.: Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur. J. Cancer (2005) 3(Suppl.):4.
   Google Scholar
• CRANE CH, ELLIS LM, ABBRUZZESE JL et al.: Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J. Clin. Oncol. (2006) 24(7):1145-1151.
   PubMed Web of Science ®Google Scholar
• BEN-JOSEF E, SHIELDS AF, VAISHAMPAYAN U et al.: Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. (2004) 59(2):454-459.
   PubMed Web of Science ®Google Scholar
• ITAKURA J, ISHIWATA T, SHEN B et al.: Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer (2000) 85:27-34.
   PubMed Web of Science ®Google Scholar
• BRUNS CJ, SOLORZANO CC, HARBISON MT et al.: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. (2000) 60:2926-2935.
   PubMed Web of Science ®Google Scholar
• MOORE M, GOLDSTEIN D, HAMM J et al.: Erlotinib plus compared to gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCNC-CTG). Proc. Am. Assoc. Clin. Oncol. (2005). (Abstract 1).
   Google Scholar
• JAVLE R, IYER R, YU J et al.: Gemcitabine, capecitabine and bevacizumab: a Phase II study for advanced pancreatic cancer (APC) patients with good performance status. Proc. Am. Assoc. Clin. Oncol. Gastrointest. Cancer Symp. (2006). (Abstract 117).
   Google Scholar
• NEOPTOLEMOS JP, STOCKEN DD, FRIESS H et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. (2004) 350(12):1200-1210.
   PubMed Web of Science ®Google Scholar